Israel Active

Teva’s new successful medication is just an example of “everyday” advances that Israeli biotechs make in the treatment of cancer sufferers.

The US Food and Drugs Administration has approved Israeli giant Teva’s generic versions of HIV drug Combivir and Alzheimer's treatment Aricept.

Israeli doctors performed a record number of transplant operations this past week. Surgeons at nine hospitals worked round the clock as Israel’s ADI donor card program proved its worth again.

Meir Korner must be the oldest person in the world to have a nose job. Skin cancer required Haifa surgeons to replace 50% of his nose with skin from his forehead.

The new Bar-Ilan University medical school in Safed will specialise in leading-edge research into treatments for cancer, heart disease, aging and infectious diseases.

Israel is the world leader in patents for medical devices, relative to population size. And the world has come to see them at the 10th annual Biomed Israel show in Tel Aviv.

A Chinese company has bought Israeli biotech D-Pharm’s DP-VPA epilepsy drug, for use in China, Hong Kong and Macau. And it hasn’t even completed trials yet.

Israel’s InsuLine Medical announced positive results in efficacy and safety trials for its InsuPatch. The patch achieved a relative median increase of 29.7% in insulin levels in the blood within an hour, compared with an insulin injection. This compares to a FDA requirement for an increase of at least 10%.

Following on from the project initiated in April 2011, Deputy Foreign Minister Danny Ayalon signed a cooperation agreement with Kenya and Germany to promote fish farming techniques and desalinate and purify the waters of Lake Victoria.